Free Trial
NASDAQ:EVFM

Evofem Biosciences (EVFM) Stock Price, News & Analysis

Evofem Biosciences logo
$0.01 0.00 (0.00%)
As of 07/3/2025 11:39 AM Eastern

About Evofem Biosciences Stock (NASDAQ:EVFM)

Key Stats

Today's Range
$0.0093
$0.0102
50-Day Range
$0.0084
$0.01
52-Week Range
$0.0061
$0.0155
Volume
39,482 shs
Average Volume
435,993 shs
Market Capitalization
$1.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Evofem Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
17th Percentile Overall Score

EVFM MarketRank™: 

Evofem Biosciences scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Evofem Biosciences.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Evofem Biosciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Evofem Biosciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    0.12% of the float of Evofem Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Evofem Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Evofem Biosciences has recently increased by 137.27%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Evofem Biosciences does not currently pay a dividend.

  • Dividend Growth

    Evofem Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.12% of the float of Evofem Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Evofem Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Evofem Biosciences has recently increased by 137.27%, indicating that investor sentiment is decreasing significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Evofem Biosciences insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 0.21% of the stock of Evofem Biosciences is held by insiders.

    • Percentage Held by Institutions

      Only 0.22% of the stock of Evofem Biosciences is held by institutions.

    • Read more about Evofem Biosciences' insider trading history.
    Receive EVFM Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Evofem Biosciences and its competitors with MarketBeat's FREE daily newsletter.

    EVFM Stock News Headlines

    Silicon Valley Gold Rush
    A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
    Evofem Biosciences Inc. Q1 Earnings Summary
    Evofem Biosciences Reports Q1 2025 Earnings
    See More Headlines

    EVFM Stock Analysis - Frequently Asked Questions

    Evofem Biosciences' stock was trading at $0.0099 at the beginning of the year. Since then, EVFM stock has increased by 1.0% and is now trading at $0.01.

    Evofem Biosciences, Inc. (NASDAQ:EVFM) posted its quarterly earnings results on Friday, June, 16th. The biotechnology company reported ($1.85) earnings per share for the quarter, beating analysts' consensus estimates of ($15.00) by $13.15. The biotechnology company had revenue of $5.81 million for the quarter. Evofem Biosciences had a negative net margin of 46.42% and a negative trailing twelve-month return on equity of 91.97%.

    Shares of Evofem Biosciences reverse split on the morning of Thursday, May 18th 2023.The 1-125 reverse split was announced on Thursday, May 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

    Shares of EVFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Evofem Biosciences investors own include Tesla (TSLA), NIO (NIO), Plug Power (PLUG), Meta Platforms (META), Sorrento Therapeutics (SRNE), NVIDIA (NVDA) and Ford Motor (F).

    Company Calendar

    Last Earnings
    6/16/2023
    Today
    7/04/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:EVFM
    Employees
    120
    Year Founded
    N/A

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    $52.98 million
    Pretax Margin
    -46.42%

    Debt

    Sales & Book Value

    Annual Sales
    $11.39 million
    Price / Cash Flow
    N/A
    Book Value
    ($2.64) per share
    Price / Book
    0.00

    Miscellaneous

    Free Float
    113,118,000
    Market Cap
    $1.19 million
    Optionable
    Not Optionable
    Beta
    -1.01

    Social Links

    20 Stocks to Sell Now Cover

    Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

    Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

    Get This Free Report

    This page (NASDAQ:EVFM) was last updated on 7/4/2025 by MarketBeat.com Staff
    From Our Partners